Related references
Note: Only part of the references are listed.Both treated and untreated tumors are eliminated by short hairpin RNA-based induction of target-specific immune responses
Wenyi Gu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Effect of blocking VEGF, hTERT and Bcl-xl by multiple shRNA expression vectors on the human laryngeal squamous carcinoma xenograft in nude mice
Shi-Ming Chen et al.
CANCER BIOLOGY & THERAPY (2008)
Combination therapy with short interfering RNA vectors against VEGF-C and VEGF-A suppresses lymph node and lung metastasis in a mouse immunocompetent mammary cancer model
M-A Shibata et al.
CANCER GENE THERAPY (2008)
Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention in a mouse model of cervical cancer
Amy L. Jonson et al.
GYNECOLOGIC ONCOLOGY (2008)
Delivery vehicles for small interfering RNA in vivo
Antonin R. De Fougerolles
HUMAN GENE THERAPY (2008)
FDG-PET/CT for the evaluation of response to therapy of cutaneous T-cell lymphoma to vorinostat (suberoylanilide hydroxamic acid, SAHA) in a phase II trial
Phillip H. Kuo et al.
MOLECULAR IMAGING AND BIOLOGY (2008)
Lentiviral vector design for multiple shRNA expression and durable HIV-1 inhibition
Olivier ter Brake et al.
MOLECULAR THERAPY (2008)
Inhibiting colorectal carcinoma growth and metastasis by blocking the expression of VEGF using RNA interference
Shaochuang Wang et al.
NEOPLASIA (2008)
Future of RNAi-based therapies for human papillomavirus-associated cervical cancer
Jiezhong Chen et al.
FUTURE VIROLOGY (2007)
Overexpression of human papillomavirus type 16 oncoproteins enhances hypoxia-inducible factor 1α protein accumulation and vascular endothelial growth factor expression in human cervical carcinoma cells
Xudong Tang et al.
CLINICAL CANCER RESEARCH (2007)
VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth
Ji Young Yoo et al.
MOLECULAR THERAPY (2007)
Silencing of HIV-1 with RNA interference: A multiple shRNA approach
Olivier ter Brake et al.
MOLECULAR THERAPY (2006)
Gene transfer in humans using a conditionally replicating lentiviral vector
Bruce L. Levine et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Inhibition of cervical cancer cell growth in vitro and in vivo with lentiviral-vector delivered short hairpin RNA targeting human papillomavirus E6 and E7 oncogenes
W. Gu et al.
CANCER GENE THERAPY (2006)
Simultaneous targeting of HCV replication and viral binding with a single, lentiviral vector containing multiple RNA interference expression cassettes
Scot D. Henry et al.
MOLECULAR THERAPY (2006)
Optimization and functional effects of stable short hairpin RNA expression in primary human lymphocytes via lentiviral vectors
Dong Sung An et al.
MOLECULAR THERAPY (2006)
Short-term induction and long-term suppression of HPV16 oncogene silencing by RNA interference in cervical cancer cells
S Tang et al.
ONCOGENE (2006)
RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin
LN Putral et al.
MOLECULAR PHARMACOLOGY (2005)
Gene codon composition determines differentiation-dependent expression of a viral capsid gene in keratinocytes in vitro and in vivo
KN Zhao et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Inhibition of hepatitis B virus gene expression by single and dual small interfering RNA treatment
KL Wu et al.
VIRUS RESEARCH (2005)
CXCR4 and CCR5 shRNA transgenic CD34+cell derived macrophages are functionally normal and resist HIV-1 infection
J Anderson et al.
RETROVIROLOGY (2005)
Regulatory considerations for novel gene therapy products: A review of the process leading to the first clinical lentiviral vector
P Manilla et al.
HUMAN GENE THERAPY (2005)
Inhibition of respiratory viruses by nasally administered siRNA
V Bitko et al.
NATURE MEDICINE (2005)
Expression of human papillomavirus type 16 E6 and E7 oncoproteins in primary foreskin keratinocytes is sufficient to alter the expression of angiogenic factors
E Toussaint-Smith et al.
ONCOGENE (2004)
Unlocking the potential of the human genome with RNA interference
GJ Hannon et al.
NATURE (2004)
Short-term cytotoxic effects and long-term instability of RNAi delivered using lentiviral vectors
RJ Fish et al.
BMC MOLECULAR BIOLOGY (2004)
Using RNAi to catch Drosophila genes in a web of interactions:: insights into cancer research
R Dasgupta et al.
ONCOGENE (2004)
siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells
K Butz et al.
ONCOGENE (2003)
In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA
M Yoshinouchi et al.
MOLECULAR THERAPY (2003)
Inhibition of HIV-1 infection by small interfering RNA-mediated RNA interference
J Capodici et al.
JOURNAL OF IMMUNOLOGY (2002)
Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference
M Jiang et al.
ONCOGENE (2002)
Modulation of HIV-1 replication by RNA interference
JM Jacque et al.
NATURE (2002)
Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways
EC Goodwin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Oncogenes and tumor angiogenesis:: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner
O López-Ocejo et al.
ONCOGENE (2000)
Accurate estimation of transduction efficiency necessitates a multiplex real-time PCR
D Klein et al.
GENE THERAPY (2000)
Share Paper
